Learnings from 30 years of reported Efficacy and Safety of Vagus Nerve Stimulation (VNS) for Epilepsy Treatment: A critical review
Since its first reported use in humans in 1988 and more than 100,000 subsequent implantations, VNS has generated growing interest in the management of drug-resistant epilepsy (DRE) . These represent around 30% of all epilepsy cases . The average prevalence of epilepsy in the world is estimated at around 7.60 cases/1,000 inhabitants, with an average annual incidence of 67.77 cases/100,000 inhabitants . The functional prognosis and survival associated with this condition are influenced by major trauma and psychiatric and cognitive comorbidities.
We have previously shown invasive vagus nerve stimulation to improve attention and working memory and alter emotion-attention interaction in patients with refractory epilepsy, suggesting that VNS might be useful in the treatment of cognitive impairment. The current research focuses on whether non-invasive, transcutaneous vagus nerve stimulation (tVNS) has similar effects to VNS. Furthermore, we aimed to assess whether tVNS has an impact on cognitive control in general or on underlying brain physiology in a task that mimics everyday life demands where multiple executive functions are engaged while encountering intervening e...
Publication date: November 2020Source: Epilepsy &Behavior, Volume 112Author(s): Nallammai Muthiah, Jun Zhang, Madison Remick, William Welch, Yoshimi Sogawa, Jong-Hyeon Jeong, Taylor J. Abel
CONCLUSIONS: Recurrent seizures caused disturbances in brainstem-cortical/subcortical FC, especially in motor executive function related regions and default mode network. VNS could reorganize the altered FC between brainstem and insula, precuneus, and cerebellum in responders. PMID: 32931055 [PubMed - as supplied by publisher]
AbstractPresent project is concerned with the possibility to modulate the neural regulation of food intake by non-invasive stimulation of the vagus nerve. This nerve carries viscero-afferent information from the gut and other internal organs and therefore serves an important role in ingestive behavior. The electrical stimulation of the vagus nerve (VNS) is a qualified procedure in the treatment of drug-resistant epilepsy and depression. Since weight loss is a known common side effect of VNS treatment in patients with implanted devices, VNS is evaluated as a treatment of obesity. To investigate potential VNS-related changes...
This study demonstrates the safety and efficacy of VNS for children with drug-resistant epilepsy (DRE) younger than six. One, two, and four years after VNS implantation, 55%, 60%, and 52% of these patients, respectively, achieved ≥50% reduction in seizure frequency. The safety of VNS is also comparable with older, better studied, age groups. Based on these data, VNS therapy should be considered for children younger than six. PMID: 32942207 [PubMed - as supplied by publisher]
AbstractBackgroundIn vagal nerve stimulation (VNS) therapy, the release of VNS model 106 (AspireSR) allowed for responsive VNS (rVNS). rVNS utilizes a cardiac ‐based seizure detection algorithm to detect seizure‐induced tachycardia to trigger additional stimulation. There are some studies suggesting clinical benefits of rVNS over traditional VNS, but the performance and significance of autostimulation mode in clinical practice are poorly understood.ObjectivesTo assess the effect of initiation of rVNS therapy and altered stimulation settings on the number of daily stimulations and energy consumption in VNS therapy and t...
Conclusions: VNS is a palliative treatment for reducing seizure frequency and intensity. Despite its economic cost, VNS should improve patients’ quality of life and reduce care needs.
The aim of our study is to evaluate objective and subjective vocal outcomes in patients undergoing vagus nerve stimulation (VNS) therapy for drug-resistant epilepsy and to assess the vocal outcome in the known laryngeal dysmotility patterns induced by VNS.We enrolled 16 adult patients without cognitive impairment who had undergone VNS implant for drug-resistant epilepsy at least 1 year prior. They were evaluated by flexible fibreoptic laryngeal examination and Voice Handicap Index questionnaire administration; acoustic and perceptual voice analysis was performed both at rest and during VNS activation.
This study aimed to use Taiwanese nationwide registry data to analyze the therapeutic effects of VNS in children with refractory epilepsy (RE) and try to explore predictive factors of VNS treatment effectiveness.
Publication date: October 2020Source: Epilepsy &Behavior, Volume 111Author(s): Proleta Datta, Krishna Mourya Galla, Kalyan Sajja, Christopher Wichman, Hongmei Wang, Deepak Madhavan